Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin/gemcitabine/bevacizumab vs carboplatin/pegylated liposomal doxorubicin/bevacizumab in platinum-sensitive recurrent ovarian cancer
DRKS00004913Phase 3Completed
- Sponsor
- AGO Research
- Start
- Apr 2013
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and gynecological cancer comparing Carboplatin + gemcitabine + bevacizumab with Carboplatin + pegylated liposomal doxorubicin + bevacizumab (2 arms). Started Apr 2013; status: completed.
02
Drugs
bevacizumabcarboplatingemcitabinedoxorubicin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)gynecological cancer
Beyond the preview
Go deeper on DRKS00004913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00004913.